Stocks · Health care · Pharmaceutical Preparations

Generate Biomedicines, Inc.

GENB
United States Fiscal year ends December CIK 0002100782 Results filed 6 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Michael Nally
4 Mar 2026
Chief Executive Officer
Buy
20,000
$12.00
$240.00K
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Jane L Mendillo
2 Mar 2026
Director
Buy
1,500
$16.00
$24.00K
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Noubar Afeyan
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Jason Silvers
2 Mar 2026
President & CFO
Buy indirect
1,000
$16.00
$16.00K
Jason Silvers
2 Mar 2026
President & CFO
Buy indirect
500
$16.00
$8.00K
Jason Silvers
2 Mar 2026
President & CFO
Buy indirect
500
$16.00
$8.00K
Beth Grous
2 Mar 2026
Chief People Officer
Buy indirect
300
$16.00
$4.80K

What was left out

Form 4 filings counted 18
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 67,320,805
History held since 2 Mar 2026